Sun Pharmaceutical Industries Ltd Key Launches And Strategic Investments
SUNPHARMA Launched Unloxcyt (USFDA-approved for squamous cell carcinoma) and Ilumya (India); acquired Checkpoint Therapeutics for oncology expansion. $100 Mn for FY26 speciality product commercialization (Leqselvi for alopecia, MM-II osteoarthritis); SCD-044 Phase 2 trials for psoriasis/atopic dermatitis.
#WatchOutFor#StockInNews#FundamentalViews
771 likes·48 comments